For more information about this new treatment, visit www.mirvaso.com. Important Safety Information - Mirvaso® Gel Indication: Mirvaso ® (brimonidine) Topical Gel, 0.33%* is an alpha adrenergic agonist ...

Please provide your email address to receive an email when new articles are posted on . Galderma Laboratories recently announced that a new pump dispenser design for Mirvaso topical gel, 0.33% is ...

MIRVASO (brimonidine) 0.33% Topical Gel Galderma has announced that in a one-year, open-label, non-comparative study, Mirvaso (brimonidine) topical gel was demonstrated to be safe and effective when ...

Rosacea is a common skin condition that causes flushing and red bumps on the face, leaving many who have the disorder feeling self-conscious about their appearance.Now, one drug is being hailed as a ...

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended marketing of brimonidine tartrate 3 mg/g topical gel (Mirvaso, Galderma) for the symptomatic ...

- Galderma portfolio expands to offer a fast onset and long-acting alpha-2 adrenergic receptor agonist - Galderma, a leading global pharmaceutical company exclusively focused on dermatology, today ...

FORT WORTH, Texas--(BUSINESS WIRE)--Galderma Laboratories, L.P., a global leader focused on medical treatment options in dermatology and skin health and the maker of Cetaphil®, today announced the ...

Mirvaso (brimonidine; Galderma) Topical Gel 0.33% is now available in a pump dispenser. Galderma announced the availability of Mirvaso (brimonidine) Topical Gel 0.33% in a new pump delivery system, ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved brimonidine topical gel, 0.33% for treatment of facial erythema of adults with rosacea, ...

Mirvaso® (brimonidine) 3 mg/g gel an alpha-2 adrenergic agonist indicated for the symptomatic treatment of the redness (facial erythema) associated with rosacea in adult patients, is now available in ...

"Mirvaso®is the only approved medicinal product that directly targets the facial redness of rosacea and provides an innovative therapy for the condition. Applied once-daily, Mirvaso®works quickly to ...

Galderma, a leading global pharmaceutical company exclusively focused on dermatology, today announced that the European Commission has granted Marketing Authorisation in Europe for Mirvaso(R) ...